| 主权项 |
1. A method for transiently immortalizing cells, comprising introducing immortalizing proteins into the cells from the exterior, wherein the immortalizing proteins employed are transforming proteins of at least one of viral oncogenes selected from SV40 TAg, JK-virus and BC-virus, HPV E6, HPV E7, adenovirus E1A and adenovirus E1B, the Epstein-Barr Virus (EBV), Epstein-Barr nuclear antigen-2 (EBNA2), human T-cell leukemia virus-1 (HTLV-1), HTLV-1 tax, Herpesvirus Saimiri (HVS), mutant p53 and of cellular oncogenes selected from one of myc, c-jun, c-ras, c-Ha-ras, h-ras, v-src, c-fgr, myb, c-myc, n-myc, and Mdm2, Bmi-1, E2F3, twist or cyclins such as cyclin E and D, cyclin-dependent kinases such as cdk 2, 4, 6, or members of the E2F transcription factor family and growth factors such as EGF and FGF and anti-apoptotic proteins, mutant cellular proteins; or wherein the immortalizing proteins employed are telomere proteins, thereby avoiding a telomere loss during expansion; and wherein the immortalizing proteins are fused to one of a messenger protein, receptor ligands and antibodies, thereby forming fusion proteins, wherein the messenger protein are selected from the group of human immunodeficiency virus (HIV) REV, a homeodomain from the Antennapedia polypeptide or Penetratin, Engrailed or Hoxa-5, a polymer of L-arginine or D-arginine amino acid residues, a polymer of L-lysine or D-lysine amino acid residues, transcription factors like BETA2/neuro D, PDX-1, nuclear localization signal, Histone derived peptides, a polymer of cationic macromolecules, FGF-1 and FGF-2, lactoferrin or; homologues or fragments thereof. |
